ZCCHC7 Knockout cell line (LoVo)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

ZCCHC7 (zinc finger CCHC-type containing 7) encodes a zinc finger-containing protein with RNA-binding activity. It is predicted to participate in nuclear RNA surveillance, suggesting a role in monitoring and processing RNA molecules within the cell. ZCCHC7 is associated with the cytosol and nucleolus, although the specific molecular mechanisms and biological functions through which it contributes to RNA surveillance remain incompletely characterized.

LoVo is a human colorectal adenocarcinoma cell line established from a metastatic tumor in the left supraclavicular region of a 56-year-old male patient. The cells produce carcinoembryonic antigen (CEA) and represent a metastatic colorectal cancer model. LoVo is used for studies of colorectal cancer biology, tumor metastasis, and cancer-related signaling mechanisms.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.